Therapeutic Landscape of Carfilzomib and Other Modulators of the Ubiquitin-Proteasome Pathway

被引：15

作者：

Mitsiades, Constantine S. ^{[1
,2
]}

机构：

[1] Dana Farber Canc Inst, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2015年 / 33卷 / 07期

基金：

美国国家卫生研究院;

关键词：

LOW-DOSE DEXAMETHASONE; REFRACTORY MULTIPLE-MYELOMA; PHASE-I TRIAL; PROTEIN-DEGRADATION; WALDENSTROMS MACROGLOBULINEMIA; IRREVERSIBLE INHIBITOR; PRECLINICAL MODELS; ANTITUMOR-ACTIVITY; QUALITY-CONTROL; AL AMYLOIDOSIS;

D O I：

10.1200/JCO.2014.55.5748

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

[No abstract available]

引用

页码：782 / 785

页数：4

共 76 条

[1] Potent and selective inhibitors of the proteasome: Dipeptidyl boronic acids [J].

Adams, J ;

Behnke, M ;

Chen, SW ;

Cruickshank, AA ;

Dick, LR ;

Grenier, L ;

Klunder, JM ;

Ma, YT ;

Plamondon, L ;

Stein, RL .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1998, 8 (04) :333-338

[2]

Aghajanian C, 2002, CLIN CANCER RES, V8, P2505

[3] The 39th David A. Karnofsky Lecture: Bench-to-Bedside Translation of Targeted Therapies in Multiple Myeloma [J].

Anderson, Kenneth C. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04) :445-452

[4]

[Anonymous], 1933, BLOOD

[5] Nonproteasomal Targets of the Proteasome Inhibitors Bortezomib and Carfilzomib: a Link to Clinical Adverse Events [J].

Arastu-Kapur, Shirin ;

Anderl, Janet L. ;

Kraus, Marianne ;

Parlati, Francesco ;

Shenk, Kevin D. ;

Lee, Susan J. ;

Muchamuel, Tony ;

Bennett, Mark K. ;

Driessen, Christoph ;

Ball, Andrew J. ;

Kirk, Christopher J. .

CLINICAL CANCER RESEARCH, 2011, 17 (09) :2734-2743

[6] Replacement of bortezomib with carfilzomib for multiple myeloma patients progressing from bortezomib combination therapy [J].

Berenson, J. R. ;

Hilger, J. D. ;

Yellin, O. ;

Dichmann, R. ;

Patel-Donnelly, D. ;

Boccia, R. V. ;

Bessudo, A. ;

Stampleman, L. ;

Gravenor, D. ;

Eshaghian, S. ;

Nassir, Y. ;

Swift, R. A. ;

Vescio, R. A. .

LEUKEMIA, 2014, 28 (07) :1529-1536

[7] Autoubiquitination of the 26S Proteasome on Rpn13 Regulates Breakdown of Ubiquitin Conjugates [J].

Besche, Henrike C. ;

Sha, Zhe ;

Kukushkin, Nikolay V. ;

Peth, Andreas ;

Hock, Eva-Maria ;

Kim, Woong ;

Gygi, Steven ;

Gutierrez, Juan A. ;

Liao, Hua ;

Dick, Lawrence ;

Goldberg, Alfred L. .

EMBO JOURNAL, 2014, 33 (10) :1159-1176

[8] 20S proteasome and its inhibitors: Crystallographic knowledge for drug development [J].

Borissenko, Ljudmila ;

Groll, Michael .

CHEMICAL REVIEWS, 2007, 107 (03) :687-717

[9] In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells [J].

Chauhan, Dharminder ;

Tian, Ze ;

Zhou, Bin ;

Kuhn, Deborah ;

Orlowski, Robert ;

Raje, Noopur ;

Richardson, Paul ;

Anderson, Kenneth C. .

CLINICAL CANCER RESEARCH, 2011, 17 (16) :5311-5321

[10] Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: A phase II study of the National Cancer Institute of Canada Clinical Trials Group [J].

Chen, Christine I. ;

Kouroukis, C. Tom ;

White, Darrell ;

Voralia, Michael ;

Stadtmauer, Edward ;

Stewart, A. Keith ;

Wright, John J. ;

Powers, Jean ;

Walsh, Wendy ;

Eisenhauer, Elizabeth .

JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (12) :1570-1575

← 1 2 3 4 5 6 7 8 →